Table 2.
Information of 12-weeks post treatment and changes in endocrine and metabolic profile.
| CANA/MET (N = 21) | MET (N = 20) | P value (Change) | |||
|---|---|---|---|---|---|
| 12 weeks | Change from baseline | 12 weeks | Change from baseline | ||
| Anthropometric characteristics | |||||
| Body weight (kg) | 75.40 ± 8.68 d | -6.66 ± 4.24 | 72.49 ± 9.97 d | -5.85 ± 3.32 | 0.5386 |
| BMI (kg/m2) | 28.62 ± 2.91 d | -2.49 ± 1.55 | 27.14 ± 3.50d | -2.20 ± 1.30 | 0.5441 |
| Gonadal hormones | |||||
| FSH (mIU/mL) | 5.84 ± 2.24 | -0.75 ± 2.51 | 5.36 ± 1.94 | -0.68 ± 2.17 | 0.9309 |
| LH (mIU/mL) | 8.59 (3.96-12.16) | -1.91 (-7.40 to 2.49) | 10.27 (8.22-13.61) | 0.42 (-7.10 to 4.19) | 0.1990 |
| TT (ng/mL) | 0.53 (0.45-0.84) d | -0.33 ± 0.23 | 0.71 (0.55-0.91) a | -0.18 ± 0.18 | 0.0233 |
| FAI (%) | 19.15 ± 13.19 a | -9.47 ± 11.65 | 14.14 ± 12.57 | -5.11 ± 7.40 | 0.1631 |
| SHBG (nmol/L) | 13.6 (9.55-24.10) | 0.10(-3.45 to 5.30) | 22.35(14.78-26.70) a | 2.95 (-2.15-10.30) | 0.4579 |
| AND (ng/ml) | 3.22 ± 1.35 | -0.36 ± 1.17 | 3.79 ± 2.21 | -0.39 ± 1.58 | 0.9555 |
| Glucose and lipid-related parameters | |||||
| FBG (mmol/L) | 5.20 (4.88-5.35) c | -0.33 (-0.95 to -0.05) | 5.30 (4.96-5.42) | -0.11(-0.49 to 0.1) | 0.1711 |
| FINS (mU/L) | 12.0 (8.20-20.15) c | -7 (-10.4 to -2) | 14.70 (10.80-20.40) b | -4.2 (-9.8 to -0.7) | 0.4565 |
| AUCGlu (mmol/L*min) | 928.3 ± 124.5 b | -158 ± 225.4 | 988.5 ± 129.0 | 2.63 ± 180.7 | 0.0182 |
| AUCIns (mU/L*min) | 10543 ± 6888 b | -4264 ± 5627 | 11691 ± 5212 | -2640 ± 6108 | 0.3869 |
| AUCIns/AUCGlu | 11.12 ± 7.12 a | -2.86 ± 5.71 | 11.76 ± 4.64 a | 0.51 ± 0.61 | 0.0164 |
| HOMA-IR | 3.14 (1.91-4.71) c | -1.83 (-3.01 to -0.96) | 3.51 (2.36-4.71) b | -1.29 (-2.9 to -0.05) | 0.4015 |
| TG (mmol/L) | 1.20 (0.84-1.63) a | -0.27 ± 0.51 | 1.43 (1.03-2.06) | -0.05 ± 0.59 | 0.2011 |
| TC (mmol/L) | 4.54 ± 0.80 a | -0.22 ± 0.43 | 4.54 ± 0.52 | -0.27 ± 0.48 | 0.7954 |
| LDL-C (mmol/L) | 2.83 ± 0.70 | -0.12 ± 0.49 | 2.83 ± 0.49 | -0.19 ± 0.50 | 0.6894 |
| Apo A1 (g/L) | 1.20 ± 0.21 | -0.02 ± 0.33 | 1.25 ± 0.26 | -0.02 ± 0.16 | 0.9465 |
| Apo B (g/L) | 0.92 ± 0.26 | -0.05 ± 0.13 | 0.90 ± 0.13 | 0.01 ± 0.17 | 0.2887 |
| Apo B/A1 | 0.78 ± 0.23 a | -0.08 ± 0.14 | 0.74 ± 0.16 | 0.02 ± 0.22 | 0.1450 |
PCOS, polycystic ovary syndrome; CANA, canagliflozin; MET, metformin; BMI, body mass index; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TT, total testosterone; FAI, free androgen index; SHBG sex hormone-binding globulin; AND, androstenedione; FBG, fasting blood glucose; FINS, fasting insulin; AUCGlu, area under the glucose curve; AUCIns, area under the insulin curve; HOMA-IR, homeostasis model assessment-insulin resistance; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo A1, apolipoprotein A1; apo B, apolipoprotein B; N/A, not applicable.
Bold and italic fonts indicate statistically significant between the two groups.
a P < 0.05, vs. baseline and 12-week visits.
b P < 0.01, vs. baseline and 12-week visits.
c P < 0.001, vs. baseline and 12-week visits.
d P < 0.0001, vs. baseline and 12-week visits.